The Landscape of Interventional Clinical Trials in Hairy Cell Leukemia.
Unnikrishnan Vaishakh V, Ali Suhair S, Chaudhary Ananya A, Shafeeq K Muhammed KM et al.
Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative malignancy characterized by the accumulation of abnormal mature B-lymphocytes in the bone marrow, spleen, and peripheral blood. Although HCL accounts for approximately 2% of all leukemias, clinical trials are essential for advancing therapeutic strategies and addressing unmet clinical needs. To analyze the landscape of interventional clinical trials in HCL registered between 1997 and 2026 and evaluate variations in trial characteristics based on intervention type, trial phase, study design, and funding source. A retrospective registry-based study was conducted using data from the U.S. National Library of Medicine ClinicalTrials.gov database. Interventional clinical trials related to HCL registered between 1997 and 2026 were included. Variables analyzed included participant characteristics, study design (allocation and masking), intervention type, trial phase, and funding source. Descriptive statistics were used to summarize trial characteristics, and temporal trends were assessed across predefined time periods. A total of 26 interventional clinical trials related to HCL were included in the final analysis. Drug-based interventions constituted most studies (n = 23; 88.46%), followed by biological interventions (n = 2; 7.69%). Most trials were conducted in Phase 2 and utilized a nonrandomized design. National Institutes of Health funding represented the largest funding source (n = 12; 46.15%), whereas industry-sponsored trials accounted for a smaller proportion. Temporal analysis demonstrated a relatively stable trend in clinical trial activity over time, with limited diversification of intervention types and no significant changes in study design characteristics across study periods. The clinical trial landscape of HCL demonstrates relatively stable trends in intervention strategies and study design. The limited trials on novel therapeutic approaches reveal ongoing research gaps, emphasizing the necessity for extensive investigation of emerging treatments to enhance the evidence base for managing HCL.